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Abstract 
Background: Breast cancer is a heterogeneous disease characterized by differential responses to targeted and 
chemotherapeutic agents. Antibody-drug conjugates are one of the promising strategies for the treatment of breast 
cancer. Monomethyl auristatin E (MMAE) is a highly potent microtubule inhibitor and a common payload used for 
development of antibody-drug conjugates. The purpose of this study was to investigate the cytotoxic effects of 
MMAE on breast cancer cell lines. 
Materials and Methods: MDA-MB-468 and MDA-MB-453 cells were treated with MMAE at various concentrations 
(1, 10, 100, and 1000 ng/ml), and cytotoxicity was measured after 48 and 72 hours using an MTT assay. 
Results: Our findings indicated that MMAE possesses dose- and time-dependent cytotoxic activities against human 
breast cancer cells. The morphological features of the treated cells were supportive of the cytotoxic activity of 
MMAE. The results of the MTT assay showed that MMAE has a significant cytotoxicity against MDA-MB-468 
and, to a lesser degree, MDA-MB-453 cells. 
Conclusion: MMAE can be used as a highly cytotoxic payload for development of antibody-drug conjugates against 
breast cancer. 
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Breast cancer is one of the most commonly diagnosed 
malignancies and the leading cause of cancer-related 
deaths in women worldwide
1
, accounting for an 
estimated 1 million new diagnoses and 400,000 deaths 
per year
2
. Several chemotherapeutic drugs have been 
approved for the treatment of breast cancer, but effective 
treatment remains elusive
3
. Monoclonal antibodies 
(mAbs) against antigens expressed on cancer cells have 
been considered as an alternative option to traditional 
cancer chemotherapy. Trastuzumab (Herceptin®), a 
humanized IgG1 mAb, is currently used for the treatment 
of breast cancer, specifically for human epidermal 
growth factor receptor 2 (HER2)-positive breast cancer. 
However, 70% of the patients with HER2-positive breast 
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cancers stop responding or lose clinical benefits by 
primary (denovo) or secondary (acquired) resistance
4
. 
Over the past years, significant efforts have been devoted 
to improve the therapeutic activity of mAbs through 
various modifications. One promising approach has been 
to incorporate antibodies and cytotoxic drugs (payloads) 
in a single molecular entity, known as antibody-drug 
conjugates (ADCs)
5
. ADCs combine the targeting 
advantages of mAbs with the cytotoxic potential of 
small-molecule payloads to enhance specific drug 
delivery in tumor cells
5-11
. Cytotoxic drugs used for 
ADCs must meet three requirements, including strong 
cell toxicity, the presence of a functional group suitable 
for the coupling to the antibody, and a definite 
mechanism of action
12
. There are a lot of cellular toxins 
known in nature, but only a small number of toxic agents 
have been found to be suitable for ADC applications. 
The payloads currently being used in ADC development 
can generally be divided into two main categories, 
microtubule inhibitors and DNA-damaging agents
13
. The 
former includes auristatins and maytansines that target 
rapidly dividing cells by interfering with different parts 
of the cell cycle
14
 whereas the latter comprises 
calicheamicins, along with the less commonly used 
cytotoxins such as duocarymycins and 




Monomethyl auristatin E (MMAE), a highly potent 
auristatin, remains a hot topic in ADC studies. MMAE is 
an antimitotic agent which inhibits cell division by 
blocking the polymerisation of tubulin, representing as 
much as 100- to 1000-fold more potent than standard 
chemotherapeutic drugs such as vinblastine
16,17
. The 
drug is currently used as a payload for development of a 
variety of ADCs, including Brentuximab vedotin 
(Adcetis®, SGN-35), an FDA-approved ADC, and more 
than fourteen ADCs in different phases of clinical trials. 
More importantly, MMAE are extensively used as a 
payload for development of ADCs against breast cancer, 
including Glembatumomab vedotin (CDX-011, phase II) 
and SGN-LIV1A (phase I)
16
. Determination of MMAE 
cytotoxic potential in breast cancer cell lines may 
increase the chances of successful ADCs for the 
treatment of breast cancer. 
In the present study, we sought to investigate the 
anticancer activity of MMAE in two kinds of breast 
cancer cell lines, MDA-MB-468 and MDA-MB-453. The 
cells were exposed to various concentrations of MMAE 
and the growth response was measured in a dose- and 
time-dependent manner. Then, cell Cytotoxicity was 
determined using the MTT assay. 
Methods 
Drug preparation: MMAE was bought from Concortis 
(San Diego, USA). Defined MMAE solutions were 
prepared, filtered using 0.22-μM-pore-size filters and 
serially diluted with the medium to obtain working 
solutions. Lastly, the working solutions were stored at 
−20˚C until the time of the experiment. 
Cell Lines: MDA-MB-468 and MDA-MB-453 (human 
breast cancer cell lines) were obtained from national cell 
bank of Iran (Pasteur Institute of Iran, Tehran, Iran). 
Cells were grown in DMEM medium supplemented with 
10% heat inactivated FBS, 100 unit/ml penicillin, 100 
μg/ml streptomycin and 0.2 mM Glotamax (Invitrogen 
Gibco), under an atmosphere of 95% humidity and 5% 
CO2 at 37°C. Cells were maintained by sub-culturing and 
passaging as monolayers in 25- and 75-cm2 cell culture 
flasks. 
Cell Culture: For the experiments, cells were detached 
by trypsin-EDTA (Sigma-Aldrich; St. Louis, MO, USA) 
at approximately 80% confluency and cultured in 96-well 
tissue culture plates (Greiner, Frickenhausen, Germany) 




. After 24 hours of 
incubation, the cells were exposed to MMAE at various 
concentrations (1, 10, 100, and 1000 ng/ml) for the next 
48 and 72 hours. Cells treated with no drug or DMSO 
were used as negative and positive controls, respectively. 
All experiments were repeated five times. Each 
experiment was performed in duplicate under the same 
conditions. 
Trypan Blue Dye Exclusion Assay: Cell suspension 
was mixed with an equal volume of 0.4% trypan blue 
reagent (Gibco Life Technologies), the solution was 
mixed thoroughly and the number of viable and 
nonviable cells was determined by trypan blue dye 
exclusion using a hemocytometer. The number of live 
cells was calculated using the following formula: % 
viability = (live cell count/total cell count)*100. 
Cellular Morphology: The effect of MMAE on cell 
morphology was determined using an inverted light 
microscope (Leica, Inc.) during 48- and 72-hour 
incubation periods. Once digital images were recorded, 
Abdollahpour-Alitappeh et al.            Monomethyl Auristatin E, a Potent Cytotoxic Payload for Development of Antibody-Drug … 
NBM                                                                                    100                                Novelty in Biomedicine 2017, 3, 98-103 
cells were trypsinized and resuspended in PBS containing 
1% FBS for further analyses. 
Cytotoxicity assay: An MTT assay (Sigma-Aldrich; St. 
Louis, MO, USA) was used to assess the in vitro 
cytotoxicity of MMAE. After 48- and 72-hour incubation 
periods, the medium was aspirated, and cells were 
washed twice with PBS. Afterwards, 20 μl/well MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide) solution (stock concentration, 5 mg/mL in 
PBS) was added to each well, and incubated for 4 hours 
in an incubator at 37°C. After the incubation period, the 
media was gently aspirated, and the formazan crystals in 
cells were dissolved in 200 μl of DMSO. The plates were 
incubated on a rotary shaker at 37°C for 1 hour to 
solubilize the formations of purple crystal formazan. The 
absorbance was measured using a microplate reader at 
570 nm. The absorbance of untreated cells was 
considered to be 100% survival. The cytotoxicity rate 
was determined using the following formula: cytotoxicity 
(%) = 100 - ((At-Ab)/ (Ac-Ab)) × 100, where At = 
Absorbance value of the drug, Ab= Absorbance value of 
the blank and Ac=Absorbance value of the negative 
control. 
Statistical analysis: Statistical analyses were carried out 
using GraphPad Prism version 6.00. Data were presented 
as mean ± standard deviation (SD) of the mean of at least 
three independent experiments. Two-way ANOVA and 
multiple comparison t test were used to calculate the 
statistical significance. p-values less than 0.05 were 
considered to be statistically significant. 
Results 
In the present study, the in vitro cytotoxic activity of 
MMAE was assessed against breast cancer cell lines in a 
dose- and time-dependent manner. Before the 
experiment, the viability of the cells was assessed by the 
trypan blue dye exclusion test; fundamentally, viable 
cells with an intact cellular membrane lack the ability to 
take up the dye (a clear appearance) while damaged 
nonviable cells take up dye through their membrane 
damages (a blue appearance). Cell viability was 
estimated to be approximately 95%. 
MDA-MB-468 and MDA-MB-453 cell lines were treated 
for 48 and 72 hours with MMAE at various 
concentrations (1, 10, 100, and 1000 ng/ml). Cells with 
no treatment were used as a negative control. The 
morphological changes of MMAE-treated cells were 
compared with the untreated cells. As illustrated in 
Figure 1, MMAE-treated cells exhibited a significantly 
altered morphology under the inverted microscope. Cells 
treated with MMAE, specifically at higher 
concentrations, appeared less uniform with the loss of 
membrane integrity, showing significant differences with 
untreated cells. Remarkable changes include loss of the 
intact membrane, cell detachment from the plate, loss of 
contact with neighboring cells, cytoplasmic 




MTT was used to determine the cytotoxic effects of 
MMAE on breast cell lines. As shown in Figure 2, 
MMAE exhibited a significant cytotoxic activity against 
MDA-MB-468 and MDA-MB-453 cells at 
concentrations ranging from 1 to 1000 ng/ml, as 
compared to the untreated cells. 
The highest cytotoxicity (p≤0.0001) was found when 
MDA-MB-468 (Figure 2A) and MDA-MB-453 (Figure 
2B) cells were treated with MMAE at a concentration of 
1 µg/ml for 72 hours, showing inhibition rates of 62.98 % 
± 5.03 and 49.455 ± 2.9, respectively. 
MDA-MB-468 cells treated with MMAE exhibited no 
significant differences between 48- and 72-hour periods 
at the same concentration, except for a concentration of 
1ng/ml (Figure 2A, p ≤ 0.05). In contrast, significant 
differences were found between different time periods in 
MDA-MB-453 cells (Figure 2B, p ≤ 0.001). However, 
MMAE could induce a dose-dependent increase in 
cytotoxicity in both cell lines. 
For further investigation, the cytotoxic activity of 
MMAE was compared in the two cell lines. As depicted 
in Figure 3, MMAE exhibits a higher cytotoxic effect on 
MDA-MB-468 cells when compared to the MDA-MB-
453 cells. Broadly speaking, the MDA-MB-468 cell line 
was shown to be more sensitive to MMAE than the 
MDA-MB-453 cell line in time- and dose-dependent 
manners. Additionally, lower concentrations of MMAE 
showed more increased cell death in MDA-MB-468 as 
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Discussion 
In this study, we demonstrated the cytotoxicty activity of 
MMAE against two kinds of breast cancer cell lines. 
Results from our study showed that MMAE is highly 
cytotoxic against breast human cancer cell lines MDA-
MB-468 and MDA-MB-453 at nanomolar 
concentrations. However, it was found that MDA-MB-
468 is more sensitive than MDA-MB-453 in both time- 
and dose-dependent manners. As shown in Figure 3, 
MMAE induced more cell cytotoxicity in MDA-MB-468 
than that in MDA-MB-453. MDA-MB-468 (ER-, PR-, 
HER2-) was found to be more sensitive than MDA-MB-
453 (ER-, PR-, HER2+). Whereas the role and 
mechanisms of HER2 overexpression on 
chemosensitivity still require intensive investigation, 
findings from a variety of studies suggest that HER2 
overexpression results in increased chemoresistance to 
certain chemotherapeutic agents. A variety of studies 
demonstrated that HER2-overexpressing breast cancer 
cells are more resistant to certain chemotherapeutic 
agents, as compared with HER2-nonoverexpressing 
breast cancer cells
19
. Yu D et al. showed that higher 
expression of HER2 in human breast cancer cell lines 
expressing HER2 correlated with resistance to paclitaxel, 
and downregulation of HER2 using an anti-HER2 mAb 
significantly sensitized the cell lines to the drug
20
. Their 
results revealed that HER2 overexpression renders 
human breast cancer cells resistant to paclitaxel
19
. In 
another study, Sellappan S et al. revealed that a human 
breast cancer cell MDA-MB-435 stably transfected with 
the HER2 gene showed no change in the expression of 
the multidrug resistance gene (MDR), but the HER2-
overexpressing transfectants were more resistant to 
paclitaxel and docetaxel than their parental cells
21
. 
Additionally, several studies have demonstrated that 
overexpression of ABCC3 (ATP-Binding Cassette 
Subfamily C Member 3) plays an important role in 
acquired multi drug resistant (MDR) in cancer cell 
lines
22,23
. Notably, Burns KE et al. showed that stable 
overexpression of ABCC3 results in in vitro resistance to 
MMAE
24
. They suggested that the ABCC3 amplicon was 
most commonly associated with the HER2-amplified 
subtypes. Nevertheless, our results showed that both cell 
lines are potentially sensitive to MMAE, when compared 
to untreated cells. We demonstrated that MMAE has the 
ability to induce cell death in MDA-MB-468 and MDA-
MB-453 cells; up to 60% cell growth inhibition was 
observed in cells treated with 1 µg/ml of MMAE, 
whereas no significant inhibition of proliferation was 
detected in untreated cells. 
 
 
Figure 1. Morphological features of MDA-MB-468 and MDA-MB-453 cells after 48- and 72-hour treatment with Monomethyl auristatin E 
(MMAE). MDA-MB-468 and MDA-MB-453 cells were treated with different concentrations (1, 10, 100, and 1000 ng/ml) of MMAE, and 
morphological changes were determined using an inverted light microscope. Significant differences were found between controls and cells treated 
with MMAE. The upper panel indicates MDA-MB-468 cells with no (A), 48-hour (B), and 72-hour (C) treatment. The lower panel represents 
MDA-MB-453 cells with no (D), 48-hour (E) and 72-hour (F) treatment. Cells exposed to MMAE showed loss of intact membrane, loss of contact 
with neighbouring cells, and detachment from the culture plate. 
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MMAE is a synthetic antineoplastic agent, which cannot 
be used as a drug itself due to its high toxicity; instead, it 
is conjugate to a mAb to form ADCs. Although under 
investigation for decades, ADCs have received renewed 
attention with the advent of significant advances in 
engineering new linker and conjugation technologies 
together with highly potent cytotoxic drugs. The most 
commonly used toxins for ADCs in clinical development 




In the present study, we selected the highly potent tubulin 
inhibitors MMAE because this agent is well 
characterized and suitable for modification to facilitate 
coupling to an antibody
25
. To date, the drug MMAE has 
been widely used to construct various ADCs. The 
MMAE-based ADCs used in the clinic trials include 
Glembatumumab vedotin (phase II)
26
 and PSMA-ADC 
(phase I)
27
. Lately, the US FDA has approved a vc-
MMAE-containing ADC, brentuximab vedotin 
(Adcetris®), for the treatment of CD30-positive Hodgkin 





MMAE represents potent antitumor activities against 
breast cancer cells, highlighting its great potential for the 
development of ADCs against breast cancer. 
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Figure 2. Effects of Monomethyl auristatin E (MMAE) on the proliferation of MDA-MB-468 (A) and MDA-MB-453 (B) cells after 48- and 72-hour 
treatment with Monomethyl auristatin E (MMAE). Different concentrations (1, 10, 100, and 1000 ng/ml) of MMAE were assessed on the cell lines, 
and the cytotoxcity rate was measured using the MTT assay after a 48- and 72-hour exposure period, as described in “Materials and Methods”. The 
data represent the mean and the error bars indicate standard deviation (SD) of two independent experiments (ns: P > 0.05, *: P ≤ 0.05, **: P ≤ 0.01, 




Figure 3. Comparison of the cytotoxic activity of Monomethyl auristatin E (MMAE) on MDA-MB-468 and MDA-MB-453 cell lines. The percentages 
for the cell cytotoxicity of MMAE-treated MDA-MB-468 cells were normalized to that of MDA-MB-453 cells. After normalization, the effect of 
MMAE on the two cell lines was compared. 
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